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OPEN
ORIGINAL ARTICLE
Elevated fetal steroidogenic activity in autism
S Baron-Cohen1,10, B Auyeung1,2, B Nørgaard-Pedersen3, DM Hougaard3, MW Abdallah3,4,5, L Melgaard3, AS Cohen3, B Chakrabarti1,6,
L Ruta1,7 and MV Lombardo1,8,9,10
Autism affects males more than females, giving rise to the idea that the inﬂuence of steroid hormones on early fetal brain
development may be one important early biological risk factor. Utilizing the Danish Historic Birth Cohort and Danish Psychiatric
Central Register, we identiﬁed all amniotic ﬂuid samples of males born between 1993 and 1999 who later received ICD-10
(International Classiﬁcation of Diseases, 10th Revision) diagnoses of autism, Asperger syndrome or PDD-NOS (pervasive
developmental disorder not otherwise speciﬁed) (n= 128) compared with matched typically developing controls. Concentration
levels of Δ4 sex steroids (progesterone, 17α-hydroxy-progesterone, androstenedione and testosterone) and cortisol were measured
with liquid chromatography tandem mass spectrometry. All hormones were positively associated with each other and principal
component analysis conﬁrmed that one generalized latent steroidogenic factor was driving much of the variation in the data. The
autism group showed elevations across all hormones on this latent generalized steroidogenic factor (Cohen’s d= 0.37, P= 0.0009)
and this elevation was uniform across ICD-10 diagnostic label. These results provide the ﬁrst direct evidence of elevated fetal
steroidogenic activity in autism. Such elevations may be important as epigenetic fetal programming mechanisms and may interact
with other important pathophysiological factors in autism.
Molecular Psychiatry advance online publication, 3 June 2014; doi:10.1038/mp.2014.48
INTRODUCTION
Autism is characterized by early developmental difﬁculties in
social interaction and communication, alongside highly repetitive
stereotyped behavior and/or restricted interests. It affects
approximately 1% of the population, and males are diagnosed
more often than females.1 While changing diagnostic practice
over time and other social variables likely partly contribute to this
male bias, biological factors related to the sex chromosomes and/
or fetal sex steroids may also have important roles.2,3 Given their
capacity to exert epigenetic fetal programming inﬂuence during
early critical periods of brain development,4–7 steroid hormones
are well-positioned as an important early fetal environmental
factor that may interact with other risk factors for autism and
other atypical neurodevelopmental conditions that asymmetrically
affect the sexes.2,8–11
Prior work has shown that one prominent sex steroid,
testosterone, has wide-ranging inﬂuence on phenotypic variability
related to autism. For example, fetal testosterone inﬂuences
individual differences in typical development in eye contact,
vocabulary size, restricted interests, mentalizing, empathy, system-
izing, attention to detail and autistic traits.11 Emerging neuroima-
ging evidence also supports a role for fetal testosterone affecting
individual differences in structural and functional brain develop-
ment in directions congruent with patterns of sexual dimorphism,
and in brain regions known to develop atypically in autism and
other sex-biased developmental psychopathologic conditions.2,9,12
The ‘extreme male brain’ theory of autism,3 which is primarily
an account about the cognitive phenotype of autism, makes
mechanistic predictions about the role of elevated fetal sex
steroids such as testosterone in the development of autism.
However, the extreme male brain theory does not exclude the role
of other mechanisms such as the role of sex chromosome effects
or the role of other steroid hormones proximal to testosterone in
biosynthesis pathways (e.g., estradiol, progesterone and cortisol).
Therefore, although prior work in relation to autism has mainly
tested fetal testosterone, it may be that the actions of testosterone
and other precursor steroid hormones within the same biosynth-
esis pathway (e.g., the Δ4 sex steroid pathway) all have signiﬁcant
roles during fetal development in autism. For example, prior
genetic association evidence has found a role for cytochrome
P450-containing enzymes in autism (e.g., CYP17A1, CYP19A1 and
CYP11B1).13 These enzymes are critical for the conversion of
different hormones along the Δ4 pathway that lead up to
testosterone (e.g., progesterone, 17α-hydroxy-progesterone and
androstenedione) as well as for conversion of Δ4 steroids such as
progesterone and 17α-hydroxy-progesterone toward cortisol (see
Supplementary Figure 1). Thus, in this study we test the role of not
only fetal testosterone but also precursor steroids within the Δ4
pathway, as well as the non-Δ4 steroid hormone cortisol, as
potential mechanisms that are elevated during fetal development
in autism.
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However, given the 1% prevalence rate, previous studies have
been too small to obtain a sample size large enough to test the
hypothesis of whether fetal steroid activity is elevated in those
who later receive a clinical diagnosis of autism. In the present
study, we overcome this limitation by examining a large biobank
of amniocentesis samples from the Danish Historic Birth Cohort
(HBC), archived at the Statens Serum Institute in Copenhagen,
Denmark. The HBC has stored amniocentesis, bloodspots and
maternal serum samples from the Danish population since the late
1970s and includes more than 100 000 samples. Using samples of
individuals born between 1993 and 1999, we linked samples in the
HBC to the Danish Psychiatric Central Register to identify all
amniotic ﬂuid samples of individuals who went on to later receive
an ICD-10 (International Classiﬁcation of Diseases, 10th Revision)
diagnosis of childhood autism, Asperger syndrome or PDD-NOS
(pervasive developmental disorder not otherwise speciﬁed).
We measured the concentration levels of sex steroids along
the CYP17-mediated Δ4 sex steroid biosynthesis pathway (i.e.,
progesterone, 17α-hydroxy-progesterone, androstenedione and
testosterone). We also measured the glucocorticoid steroid
hormone cortisol, because it is well known as a fetal programming
mechanism associated with a number of atypical phenotypes such
as anxiety disorder and attention deﬁcit-hyperactivity disorder10
that commonly co-occur with autism.14 Cortisol is also positively
correlated to sex steroid levels such as testosterone in both
amniotic ﬂuid and fetal plasma,15,16 but its position outside the Δ4
sex steroid pathway (see Supplementary Figure 1) allows for
testing neuroendocrine speciﬁcity of any potentially atypical fetal
steroidogenic activity in autism. Given prior work,2,3 we predicted
there would be elevated levels of steroidogenic activity across all
subgroups on the autism spectrum and across all Δ4 sex steroid
hormones, but predicted no difference in cortisol levels.
MATERIALS AND METHODS
Participants
Participants were selected from a population of singleton births between
the years 1993 and 1999 (n= 19 677) whose amniotic ﬂuid samples were
stored within the HBC.17 Our study is restricted to individuals born
between 1993 and 1999 because quality control analyses on typically
developing control individuals born between 1982 and 1992 showed
marked signs of changes in concentration levels compared with individuals
born between 1993 and 1999 that are likely because of evaporation and a
systematic change in the caps used for sealing the tubes that begun in
1993 (see Supplementary Information). Between November 2009 to
January 2010, we searched the HBC and Danish Psychiatric Central
Register and identiﬁed all cases with an ICD-10 diagnosis of PDD codes
(F84.0: childhood autism; F84.5: Asperger syndrome; F84.1: atypical autism;
F84.8: other PDDs; F84.9: PDD, unspeciﬁed). After data-quality ﬁltering was
applied (see Figure 1), the number of total female autism cases was small
(n=24) and preliminary analysis of non-hormonal variables indicated that
female autism cases had signiﬁcantly older fathers at birth (autism
mean= 37.45 years, s.d. = 7.20; control mean= 34.50 years, s.d. = 5.52; t
(81) = 2.01, P=0.04) and weighed less than controls (autism mean= 3142.8
g, s.d. = 490.73; control mean= 3404.4 g, s.d. = 557.41; t(81) = 2.00, P= 0.04).
Such problems were not apparent for male autism cases and thus all
analyses were conducted on males only. Typically developing controls
came from randomly selected sample of individuals from the HBC with no
known neuropsychiatric diagnoses. The ﬁnal sample sizes in all analyses
are n= 217 controls and n=128 autism. Among the autism group,
individuals comprised the following ICD-10 subdiagnoses: n=41, F84.0:
childhood autism; n= 29, F84.5: Asperger syndrome; n= 4, F84.1: atypical
autism; n= 15, F84.8: other PDDs; n= 39, F84.9: PDD, unspeciﬁed. However,
all analyses treated autism as one group rather than splitting among sub-
diagnostic labels.
Sample storage and hormone assays
Amniotic ﬂuid samples in the HBC were centrifuged immediately after
collection and the supernatants were kept at − 20 °C, following the routine
procedure for storing and handling biologic materials at the Statens
Serum Institute.18 Hormone assays took place at the beginning of
2010 and consisted of liquid chromatography tandem mass spectro-
metry of concentration levels of progesterone, 17α-hydroxy-progesterone,
androstenedione, testosterone and cortisol. We computed a variable
for ‘storage time’ based on the difference between time at which the
assays were carried out and an individual’s year of birth. All calibrators,
controls, internal standards and μ-titer plates were purchased from Perkin-
Elmer (Waltham, MA, USA) via their CHS Steroid Proﬁling Kit for mass
spectrometry (Perkin-Elmer). Formic acid was purchased from Merck
(Darmstadt, Germany). Ammonium acetate and zinc sulfate heptahydrate
were purchased from Sigma-Aldrich (St Louis, MO, USA). Water was
puriﬁed using a Millipore water puriﬁcation unit (Millipore, Billerica,
MA, USA).
The liquid chromatography tandem mass spectrometry system con-
sisted of an Aria TLX2 system (Thermo Fisher Scientiﬁc, Waltham MA, USA)
with two Agilent 1100 binary pumps and two Agilent 1200 quaternary
pumps (Agilent, Santa Clara, CA, USA) connected to a Thermo TSQ Ultra
triple quarupole mass spectrometer equipped with a atmospheric pressure
chemical ionization ion source. Extraction was performed using a Cyclone
P 0.5 × 50mm2 TurboFlow column (Thermo) and analytical separation was
achieved using Kinetix 2.6 μ 2.1 × 50mm2 C18 columns (Phenomenex,
Torrance, CA, USA). The following solvents were used: loading buffer A was
composed of 5% methanol, 95% water containing and 0.1% formic acid
(LA), loading buffer B was composed 100% methanol containing 10
mmol l− 1 ammonium acetate (LB), eluting buffer A was comosed of 2%
methanol and 98% water (EA) and eluting buffer B (EB) was identical to LB.
The analytes were trapped on the TurboFlow extraction column using 100
LA at a ﬂow rate of 1.5 ml min− 1. After 60 s, the analytes were transferred
to the analytical column using 100 μl of LB at a ﬂow rate of 0.15ml min− 1
for a duration of 60 s. The transferred analytes were concurrently diluted
using 60% EA and 40% EB at a ﬂow rate of 0.3 ml min− 1. Subsequently, the
analytes were separated before mass spectrometry analysis using gradient
elution from 53% EA/47% EB to 35.5 EA/64.5% EB at a ﬂow rate of
0.4 ml min− 1.
The mass spectrometry system was operated in a positive mode using
atmospheric pressure chemical ionization. The following source settings
were used: discharge current 5 mA, vaporizer temperature 450 °C, sheath
gas pressure 25 a.u., ion sweep gas pressure 0 a.u., auxiliary gas pressure
25 a.u., capillary temperature 300 °C and collision pressure 1.5 mTorr.
Collision voltages and T-lens voltages were optimized for each transition.
For the analytes, the following transitions were used: progesterone
(315.1/97,315.1/109), 17α-hydroxy-progesterone (331.1/97, 331.1/109),
androstenedione (287.1/97, 287.1/109), testosterone (289.1/97, 289.1-
/109) and cortisol (363.1/97, 363.2/121). For the internal standards, the
following transitions were used: progesterone-d9 (324.2/100, 324.2/113),
17α-hydroxy-progesterone-d8 (339.2/100, 339.2/113), androstenedione-d5
(292.2/100, 292.2/113) and testosterone-d5 (294.2.1/100, 294.2/113) and
cortisol-d3 (366.3/97, 366.3/121).
Calibrators and controls were reconstituted with water according to the
kit insert. A deproteinizing solution consisting of 18 g l− 1 zinc sulfate
heptahydrate in 80% methanol/20% water containing internal standard
was prepared. Fifty microliters of amniotic ﬂuid samples, calibrators and
controls were pipetted onto a 98-well μ-titer plate. One hundred micro-
liters of deproteinizing solution was added to precipitate proteins from
the samples. The plate was sealed with a silicone plate map and was
incubated at − 20 °C for 4 h. The plate was centrifuged at 4000 r.p.m. and
the supernatant was transferred to a new μ-titer plate. The plate was
covered with aluminum sealing foil and was placed in the autosampler
prior analysis.
Statistical analysis
Before data analysis, we ﬁrst implemented data-quality selection criteria.
We excluded all individuals where duplicate assays resulted in a difference
>3 s.d. from the entire sample. We also excluded outliers whose con-
centration levels were greater than the 99th percentile deﬁned based on
the entire sample born between 1993 and 1999. These outliers were
determined to be primarily artifactual in origin, given that testosterone
concentrations for these outliers were far above the maximum concentra-
tion values ever observed in prior studies of fetal testosterone either in our
or independent laboratories.11,16 Given that changes in sample concen-
tration due to storage-related factors are well-known issues19 (see
Supplementary Information), the exclusion of such extreme outliers helped
guard against this artifactual inﬂuence.
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To investigate associations between hormones in each group, we
computed the correlation matrices estimated via robust regression to allow
for insensitivity to bivariate outlying data points. We also ran principal
component analysis (PCA) implemented with pca.m in Matlab R2012B after
preprocessing the dataset via z-scoring. PCA was conducted to inspect the
latent structure of the dataset and to conﬁrm that one latent variable related
to generalized steroidogenic activity was driving a large proportion of the
variance in the dataset. After running PCA, we ran our main hypothesis tests
as one-way analysis of variances (ANOVAs) on the PCA scores (5 ANOVAs;
one per component) and evaluated the results at a Bonferroni-corrected α-
level of Po0.01. To check that maternal age, paternal age, birth weight,
gestational age at amniocentesis and storage time did not contribute to
confounding inﬂuences on the hypothesis tests, we re-ran hypothesis tests
as ANCOVAs with these variables included as covariates.
At a descriptive level of analysis, we next assessed the pattern-
ing of the group differences along the ﬁrst principal component across all
hormones and all ICD-10 autism subdiagnoses. To achieve this, we
reconstructed the data in its original space by multiplying the ﬁrst principal
component scores with its loading coefﬁcients (i.e., matrix multiplication of
the ﬁrst PC scores against the transposed vector of the ﬁrst PC loading
coefﬁcients) and then reversed the z-scoring process to have the data back
on its original scale. Once this was done, we used dot plots to plot
individual data points and also plotted the mean and 95% conﬁdence
intervals on top of the individual dots for all hormones separately and all
ICD-10 subgroups separately. No further statistical tests were carried out at
this point and this process is merely for descriptive purposes, to illustrate
how each hormone and ICD-10 subgroup contribute to the differences
within the ﬁrst principal component.
While we view the hypothesis tests on the PCA scores as a more
parsimonious approach to the dataset, we also ran hypothesis tests on the
raw data to verify whether similar inferences would remain without having
PCA transform the data along latent variables. Here, we implemented a
multivariate analysis of variance on raw hormone concentration levels and
re-ran the analysis again after including maternal age, paternal age, birth
weight, gestational age at amniocentesis and storage time as covariates.
RESULTS
Ninety-ﬁve percent or more of individuals from each group had
Apgar scores >6 at 5 min after birth, indicating that almost all
participants in this study were classiﬁed as healthy at birth. Non-
hormonal variables of interest such as maternal and paternal age,
birth weight and gestational age at amniocentesis did not differ
between groups. Furthermore, ruling out storage time as a possible
confound, we found that groups did not differ in terms how long
samples were kept in storage (see Table 1). Demonstrating that
Historic Birth Cohort (HBC) at Statens
Serum Institute, Denmark (n>100,000)
All ICD-10 autism individuals born
between 1993-1999 with an amniotic
fluid sample (n=171; ~0.8% of n=19,677
population born between 1993-1999
w/ viable amniotic fluid sample)
Autism females
(n=30)
Autism males
(n=141)
PDD-NOS
F84.1-3,
F84.8-9 (n=64)
Data quality selection criteria applied. Exclude if difference between duplicate assays > 3 standard deviations.
Also exclude outliers > 99%-tile. Exclude one individual with Childhood Disintegrative Disorder (F84.3).
Control individuals born between
1993-1999 without any other
psychiatric diagnoses, learning
difficulties, MR, or other
neurological conditions (n=307)
Final male PDD-NOS
group; F84.1, F84.8,
and F84.9 (n=58)
Control males
(n=238)
Control females
(n=69)
Final male
Control group
(n=217)
Final male
childhood Autism
group; F84.0 (n=41)
Final autism
females
group (n=24)
Final Control
females group
(n=59)
Non-autism individuals
w/ sufficient amniotic
fluid volume for further
analysis (n=691)
All individuals with ICD-8 or
ICD-10 diagnosis of autism born
between 1982-1999 and with an
amniotic fluid sample (n=414)
Singletons born between
1982-1999 with an amniotic
fluid sample (n=57,337) Non-autism individuals
randomly selected. Approx.
double the autism group.
Frequency matched on year
of birth and sex (n=820)
Individuals excluded for low
amniotic fluid volume
(Autism n=86)
(Non-autism n=129)
Individuals born between 1982-1992
excluded from further analysis after
quality control analyses on non-
autism indicated sample degradation
in pre1993 samples (Autism n=157)
(Non-autism n=298)
Autism individuals w/
sufficient amniotic fluid
volume for further
analysis (n=328)
Non-autism individuals born
between 1982-1999 excluded
because of other childhood
psychiatric diagnoses (n=86)
Childhood
Autism F84.0
(n=46)
Asperger
Syndrome (AS)
F84.5 (n=31)
Final male
AS group;
F84.5 (n=29)
Figure 1. Flowchart depicting population, selection criteria and stratiﬁcation into samples used for ﬁnal analyses. This ﬂowchart shows the
original population sizes within the Historic Birth Cohort (HBC) and the population from which our study was drawn from (individuals born
between 1993 and 1999). Red boxes indicate steps where data were selected or excluded. AS, Asperger syndrome; PDD-NOS, pervasive
developmental disorder not otherwise speciﬁed; MR, mental retardation.
Elevated fetal steroidogenic activity in autism
S Baron-Cohen et al
3
© 2014 Macmillan Publishers Limited Molecular Psychiatry (2014), 1 – 8
these factors do not differ on average between groups is important
given that many have prior links to autism, as well as their general
importance as health-related fetal programming inﬂuences.
However, although there were no signiﬁcant between-group
differences on any of these variables, we continued to view these
variables as covariates in further analyses.
Given the close proximity between the measured hormones
within steroidogenic biosynthesis pathways and prior work
suggesting positive relationships between steroid hormones, such
as testosterone and cortisol in fetal development,15,16 we
examined relationships between all measured hormones. Irre-
spective of group membership, concentration levels of all
hormones were positively related (Figures 2a and b). This suggests
one underlying latent ‘steroidogenic’ factor driving concentration
levels in the amniotic ﬂuid. Quantitative conﬁrmation of this
hypothesis can be seen in the results of a PCA, which revealed one
prominent component explaining 49.47% of the variance in the
data, and all ﬁve hormones loaded relatively equally onto it. The
other four components explained substantially smaller amounts of
variance (o17%) and loaded predominantly onto two or three
hormones (Figures 2c and d). A scree plot of the eigenvalues
(Figure 2d) shows an ‘elbow’ at component 2 and eigenvalues are
all below 1 for components 2–5. Given that PCA allowed for
parsimonious unsupervised separation of various sources of
variation in the dataset, we went ahead with main tests of our
hypotheses based on the PCA scores for each component.
One-way ANOVAs on the PCA scores for each component
(coding all individuals with autism the same irrespective of their
ICD-10 subgroup) revealed that only the ﬁrst principal component,
reﬂecting a latent generalized steroidogenic factor, was signiﬁ-
cantly different between groups (F(1,343) = 11.18, P= 0.000915,
Cohen’s d= 0.37), and this was driven by elevations in the autism
group (Figure 3a). No other components revealed any between-
group differences (PC2: F(1,343) = 0.025, P= 0.87, Cohen’s d=
− 0.01; PC3: F(1,343) = 0.73, P= 0.39, Cohen’s d=− 0.09; PC4: F
(1,343) = 0.42, P= 0.51, Cohen’s d= 0.07; PC5: F(1,343) = 0.30,
P= 0.58, Cohen’s d= 0.06). Including other non-hormonal variables
such as paternal age, maternal age, birth weight, gestational age
at the time of amniocentesis and storage time as covariates did
not change any of the inferences (PC1: F(1,334) = 11.01, P= 0.001;
PC2: F(1,334) = 0.27, P= 0.59; PC3: F(1,334) = 0.79, P= 0.37; PC4: F
(1,334) = 0.70, P= 0.40; PC5: F(1,334) = 0.18, P= 0.67). Furthermore,
similar inferences are obtained using a multivariate analysis of
variance on raw concentration levels (Wilk’s Λ= 0.964, P= 0.029)
and when including non-hormonal covariates (Wilk’s Λ= 0.962,
P= 0.023) (see Table 2 for descriptive statistics on the raw
concentration levels).
We next went further into describing the nature of differences
in the ‘steroidogenic’ component by reconstructing the data in
its original space from the coefﬁcients and scores from the
ﬁrst principal component. This reconstruction allowed us to
visualize descriptively the patterns of data from this steroidogenic
component for each hormone separately, as well as for each
ICD-10-deﬁned autism subgroup. Elevations are prominent across
all hormones, and similar irrespective of ICD-10 autism subgroup
(Figures 3b–f).
DISCUSSION
This is the ﬁrst study to test directly the prediction that fetal
steroidogenic activity is elevated in autism. We ﬁnd that amniotic
ﬂuid steroid hormones are elevated in those who later received
diagnoses on the autism spectrum. Rather than the abnormality
being restricted to a speciﬁc steroid hormone, a latent steroido-
genic factor is elevated, which includes all hormones in the
Δ4 pathway, as well as cortisol. This observation suggests dysregu-
lation of pathways mediated by cytochrome P450-containing
enzymes that catalyze the conversion of hormones along the Δ4
and glucocorticoid pathways. Prior evidence pointing toward the
importance of such enzymes was previously found via genetic
associations between autism and single-nucleotide polymorph-
isms in CYP17A1, CYP19A1 and CYP11B1 genes.13
The source of elevated steroidogenic activity in the fetal
development of autism was not tested in the current study, and
more research will be needed to understand how different
sources such as the fetus, mother, placenta or other environ-
mental factors might contribute to such elevations. While there
are robust sex differences in amniotic ﬂuid testosterone (see meta-
analysis in Supplementary Table 2 as well as documented sex
differences in typically developing controls in this cohort in
Supplementary Figure 7) that suggest that the fetus is a primary
source,20 some research has documented correlations between
amniotic ﬂuid levels and maternal plasma that would suggest that
maternal–placental–fetal transfer is another possible source.16,21,22
Recent work also suggests that the placenta is capable of
synthesizing sex steroids de novo from maternal substrates
(cholesterol), maternal or fetal prohormones and steroid
precursors.23 Active steroids produced in the placental unit can
be released into both the maternal and fetal compartments to
maintain the pregnancy and fetal development.24 In addition,
endocrine disrupting compounds may be another source of
environmentally mediated inﬂuence on the early fetal hormonal
environment and autism.25 Each of these sources require further
investigation to determine how such inﬂuences might affect fetal
development in autism.
Fetal steroidogenic abnormalities in autism are also important
because of their known interactions with other ﬁndings in the
early development of autism. Steroids and their receptors act as
epigenetic fetal programming inﬂuences on early brain develop-
ment. Through their nuclear hormone receptors, steroids can alter
gene expression via direct or indirect inﬂuence on multiple
epigenetic processes such as histone acetylation, DNA methyla-
tion and have transcriptional and post-transcriptional effects on
noncoding mRNAs such as microRNAs. Furthermore, during early
Table 1. Sample characteristics
Group variable Controls
(n= 217)
Childhood
autism
(F84.0; n= 41)
Asperger
syndrome
(F84.5; n=29)
PDD-NOS
(F84.1, F84.8,
F84.9; n= 581)
ANOVA
F(3,341)
P-value
Maternal age (years) 33.59 (5.03) 34.12 (5.89) 33.52 (5.34) 32.32 (6.15) 1.11 0.34
Paternal age (years) 35.59 (6.53) 37.29 (7.21) 33.69 (6.06) 35.03 (8.13) 1.48 0.21
Birth weight (g) 3529.45 (662.01) 3659.75 (802.10) 3432.41 (622.77) 3446.63 (543.06) 0.93 0.42
Gestational age at sampling (weeks) 14.94 (1.95) 15.02 (1.33) 15.41 (1.74) 15.06 (1.71) 0.56 0.63
Apgar (% of sample w/ score >6) 99% 95% 100% 100% — —
Storage time (years) 14.78 (1.64) 14.63 (1.84) 14.41 (1.80) 14.84 (1.63) 0.54 0.65
Abbreviations: ANOVA, analysis of variance; PDD-NOS, pervasive developmental disorder not otherwise speciﬁed. Means and s.d. (within parentheses) are
given for each group along with the F-statistic and P-value from an ANOVA testing for between-group differences.
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sensitive periods of brain development, there are sex differences
in DNA methylation, methyl-binding proteins, chromatin mod-
iﬁcations and microRNA expression, and these effects are
mediated in part by early steroid hormone effects.4–6
Early steroid-mediated epigenetic inﬂuence can also be
observed via genomic or non-genomic inﬂuences on neurodeve-
lopmental processes/mechanisms thought to be atypical in
autism, such as neurogenesis, apoptosis, neurotransmission and
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synapse formation/function and the immune system,26,27 and may
also be important for understanding early pathophysiological
mechanisms for autism.2 For example, steroid receptors upregu-
late Wnt signaling through their action on β-catenin,28 a molecule
that has a crucial role in cell-to-cell adhesion. Atypical cell-to-cell
adhesion could potentially underlie minicolumnopathy29 and
other abnormalities at the synapse in autism.30 Interestingly, a
prominent autism-candidate gene involved in synapse formation,
NLGN4X, shows sex-biased differential exon usage that is
particularly pronounced during fetal development.31 Sex steroids
also inﬂuence early developmental changes in GABAergic
signaling.32 Given known abnormalities in GABAergic signaling
in autism, elevations in early fetal sex steroids may modulate
GABAergic control of the excitatory/inhibitory balance in the
developing autistic brain.33,34 Steroid hormones also interact with
the immune system and a striking example of this is how early sex
steroids inﬂuence sexual dimorphism in the brain and behavior
through their effects on microglia activation.26 Many studies have
observed a wide array of atypicalities in the immune system in
autism.35 Converging with the current results, we previously found
atypical chemokine and cytokine proﬁles in both amniotic ﬂuid
and neonatal bloodspots of individuals with a diagnosis of autism
in the HBC.36–38 These arguments point to the need for further
work investigating interactions between fetal programming
effects of steroid hormones and other early pathophysiological
mechanisms in autism.
The current results may also be relevant to the literature on
prenatal stress and autism. We found that cortisol, a biomarker
typically associated with stress, is elevated early in the fetal
development of autism. Studies of prenatal stress in autism have
been mixed and vary substantially in methodological detail.39,40
While the current results may suggest a link between prenatal
stress and autism via heightened fetal cortisol, it is unclear if the
association here is due to heightened prenatal stress or is driven
by a more primary fetal sex steroid inﬂuence that has a side effect
of boosting fetal cortisol levels. Furthermore, although cortisol is a
prominent stress hormone at later points in development, it may
have different functions at earlier stages of brain development. As
mentioned earlier, unlike in adulthood, cortisol and sex steroids
such as testosterone are positively related to each other in fetal
development15,16 and this may suggest a more varied role for
cortisol in early brain development. The current work is consistent
with prior suggestions of interactions between the fetal hypotha-
lamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes,
and their known fetal programming effects on later atypical
neurodevelopmental phenotypes.41
From a clinical standpoint, the current results say nothing about
the potential for such data as a prospective prenatal test of autism
risk. The current ﬁndings are based on average-level group
differences that are useful for hypothesis testing but are not
directly applicable for prediction of individual diagnoses. Further
work examining the predictive utility of these and other fetal
markers is necessary to evaluate their implications for clinical
screening. Finally, the present results should not be used as
empirical justiﬁcation for treatments that target sex steroids. The
androgen-blocker Lupron has already been inappropriately
offered42 as a treatment for autism. Aside from the ethical and
safety issues this type of treatment raises, there is little conceptual
rationale to justify its use in autism since an elevation in
steroidogenic activity in early (fetal) development has no direct
implications for the use of androgen-blocking drugs later in life.
‘Organizational’ effects of sex steroids on early fetal brain develop-
ment tend to create permanent, irreversible changes in how the
brain is organized at the cellular level7,27 and such treatments
much later in life may be incapable of reversing such effects.
This study has certain limitations. First, data from central
registries do not allow for collection of detailed information about
clinical symptoms to validate diagnoses against gold-standard
instruments. However, other studies have shown that within the
Danish Psychiatric Central Register the validity ratio for childhood
autism cases is 94% for 1990–1999.43 Second, hormones were
assayed from a historic collection of amniocentesis samples stored
over several years at − 20 °C. Analyte concentration levels are
known to change over time, especially when the time period
stretches over 10 years.19 However, for the cohort analyzed in this
study (born between 1993 and 1999), storage-time-dependent
changes are unlikely to be a major issue. For instance, groups did
not systematically differ in storage time and inclusion of this and
other key variables as covariates did not change any inferences.
Furthermore, concentration levels of testosterone were in line
with levels typically observed across the literature and robust sex
differences in testosterone were apparent as was the known
prenatal surge peaking around gestational weeks 14–16 (see
Supplementary Figure 7). In addition, the use of PCA-enabled
unsupervised separation of various sources of variation in the data
and highlighted the latent steroidogenic component. Even if
variation due to storage-time-dependent changes affected the
data from the ﬁrst principal component of our analyses, there is no
reason to suspect a bias toward inﬂating the concentration levels
in one group relative to the other. Aside from PCA, a multivariate
analysis of variance on the raw concentration levels also revealed
elevations in the autism group. This suggests that while some
storage-time-dependent changes are unavoidable in historic
collections, it did not prevent our ability to test the main hypo-
thesis. Finally, the prevalence estimate of autism within this
amniocentesis cohort (0.8%) is consistent with prevalence
estimates of autism in the Danish population during the same
time period.44 Thus, although these results are derived from a
selected sample, they may be representative of what would be
expected in the general population. Nevertheless, future work on
a sample more representative of the general population is
necessary, as are tests of autism against other neurodevelop-
mental conditions that are asymmetrically affected across
the sexes.
The current results provide initial support for a fetal steroid
theory in explaining some aspects of early epigenetic risk for
autism and/or other sex-biased neurodevelopmental conditions
occurring during periods of fetal brain development. There are
Table 2. Descriptive statistics for each hormone and each group
Control (n= 217) All autism
(F84.0, F84.1, F84.5,
F84.8, F84.9; n=128)
Childhood
autism
(F84.0; n=41)
Asperger
syndrome
(F84.5; n=29)
PDD-NOS
(F84.1, F84.8,
F84.9; n= 58)
Progesterone 49.2085 (26.7755) 59.2323 (33.3872) 65.0100 (33.8850) 60.6800 (37.0477) 54.4243 (30.9040)
17α-Hydroxy-progesterone 1.5056 (0.5494) 1.6853 (0.5988) 1.6722 (0.5246) 1.7059 (0.5331) 1.6843 (0.6826)
Androstenedione 0.9701 (0.4793) 1.1223 (0.7282) 1.0590 (0.4866) 1.0310 (0.3673) 1.2128 (0.9662)
Testosterone 0.7850 (0.3681) 0.8523 (0.4009) 0.8224 (0.4080) 0.9590 (0.4568) 0.8202 (0.3625)
Cortisol 0.3384 (0.1748) 0.3739 (0.2115) 0.3637 (0.1564) 0.3272 (0.1245) 0.4050 (0.2721)
Abbreviations: PDD-NOS, pervasive developmental disorder not otherwise speciﬁed. Mean and s.d. values are in units of nmoL/L.
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several promising directions for further testing this theory. Other
steroid pathways (e.g., the Δ5 pathway, other glucocorticoids
hormones), and particularly, estradiol, must be investigated in
future work. Estradiol has long been known in non-human species
to have potent masculinizing effects on the brain and behavioral
development.45 In a prior study, we found genetic association
evidence for autism in the CYP19A1 gene, which codes for the
protein aromatase that converts testosterone to estradiol. Gene
expression levels of an autism-associated gene, retinoic acid-
related orphan receptor-α (RORA), are lowered by testosterone
and elevated by estradiol, and transcriptionally regulates several
autism-associated genes including CYP19A1, thus affected aro-
matase levels.46,47 Although we were unable to test estradiol in
the current study owing to lack of an automated liquid
chromatography tandem mass spectrometry assay, we intend to
investigate this in future work.
It is also necessary for future work to test if such elevations are
speciﬁc to autism or are shared by other neurodevelopmental
conditions with skewed sex ratios, and to test whether similar
elevations exist in females with autism. Given the comorbidity of
autism with other sex-biased conditions such as attention deﬁcit-
hyperactivity disorder, anxiety disorder and conduct disorder and
associations between these conditions and prenatal stress,14,48 it
may be that elevations in fetal steroid activity are not speciﬁc to
autism. However, even if there is no speciﬁcity for elevations in
autism, this would not necessarily detract from the signiﬁcance of
the results, as the elevations in autism may be more speciﬁc to
the phenotype when observed in combination with other risk
factors for autism that steroid hormones abnormalities may
interact with in early development. Finally, given the evidence for
positive correlations between all Δ4 steroids and non-Δ4 steroid
hormones such as cortisol in early fetal development, future work
should investigate interactions between hypothalamic-pituitary-
adrenal and hypothalamic-pituitary-gonadal axes in early brain
development.
In conclusion, we report the ﬁrst direct evidence that
steroidogenic activity is elevated in fetal development of those
who later receive diagnoses on the autism spectrum. These results
raise new questions for understanding a wide array of other
observations about the early development of autism, through
their interactions with early fetal steroidogenic abnormalities and
provide initial support for the importance of fetal steroid
hormones as important epigenetic fetal programming mechan-
isms for autism.
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